Arginine could boost brain cancer vaccine success

University of Colorado Cancer Center researchers have discovered that arginine, an amino acid that's available over-the-counter, could re-energize cancer-fighting T-cells that are suppressed in patients with gliblastoma, or brain cancer. That could give the body an additional boost needed to fight the cancer. "Our overall goal is to improve the efficacy of immunotherapy for glioblastoma," said researcher Dr. Allen Waziri on the CU Cancer Center's blog. "It's likely that this will require a two-stage approach, including stimulation of the immune system with something like a tumor vaccine while simultaneously targeting the suppressive effects of tumors on the immune system." Report

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.